WO2021216605A1 - Vaginal light therapy devices and methods for using them - Google Patents
Vaginal light therapy devices and methods for using them Download PDFInfo
- Publication number
- WO2021216605A1 WO2021216605A1 PCT/US2021/028235 US2021028235W WO2021216605A1 WO 2021216605 A1 WO2021216605 A1 WO 2021216605A1 US 2021028235 W US2021028235 W US 2021028235W WO 2021216605 A1 WO2021216605 A1 WO 2021216605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- light
- light sources
- expandable member
- vaginal
- stiffening body
- Prior art date
Links
- 238000001126 phototherapy Methods 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 230000002070 germicidal effect Effects 0.000 claims abstract description 22
- 239000012528 membrane Substances 0.000 claims description 46
- 210000001215 vagina Anatomy 0.000 claims description 30
- 239000000835 fiber Substances 0.000 claims description 26
- 210000003484 anatomy Anatomy 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 7
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 239000013013 elastic material Substances 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 206010017533 Fungal infection Diseases 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 239000012530 fluid Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 10
- 229940121375 antifungal agent Drugs 0.000 description 10
- 208000037009 Vaginitis bacterial Diseases 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 208000031888 Mycoses Diseases 0.000 description 8
- 206010046914 Vaginal infection Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 208000035143 Bacterial infection Diseases 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 230000000843 anti-fungal effect Effects 0.000 description 7
- 208000022362 bacterial infectious disease Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 201000008100 Vaginitis Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 208000028659 discharge Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003716 rejuvenation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 208000007027 Oral Candidiasis Diseases 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000287411 Turdidae Species 0.000 description 2
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229940000973 monistat Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0601—Apparatus for use inside the body
- A61N5/0603—Apparatus for use inside the body for treatment of body cavities
- A61N2005/0611—Vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
Definitions
- the present application generally relates to medical devices and, more particularly, to vaginal light therapy devices, e.g., for treatment of bacterial and fungal infections, and to systems and methods for using such devices.
- Vaginitis is characterized by inflammation of the vagina that results in discharge, itching and pain.
- the cause is usually due to a change in the normal balance of vaginal bacteria or an infection.
- the symptoms range from mucus-like discharge, itching, aching, pain during intercourse to odor.
- the vaginal infections often have multiple causes that present challenging cases for treatment.
- Bacterial vaginosis also known as vaginal bacteriosis or Gardnerella Vaginitis is a disease of the vagina caused by excessive bacteria growth. Common symptoms include increased vaginal discharge that often smells fishlike. The discharge is usually white or gray in color. Burning with urination may also occur. Itching is uncommon. Occasionally there may be no symptoms. Having bacterial vaginosis increases the risk of infection by a number of other sexually transmitted infections including HIV/AIDS. It also increases the risk of early delivery among pregnant women. Bacterial vaginosis is caused by an imbalance of the naturally occurring bacteria in the vagina. Diagnosis is suspected based on the symptoms and may be verified by testing the vaginal discharge and finding a higher than normal vaginal pH and large numbers of bacteria.
- Bacterial vaginosis is often confused with a vaginal yeast infection. Usually treatment is through the use of antibiotics. Bacterial vaginosis is the most common vaginal infection in women of reproductive age. The percentage of women affected at any given time varies but can be as high as 35%. Antibiotics, administered either orally (e.g., metronidazole) or vaginally (e.g., clindamycin, metronidazole) are effective in treatment. About 10% to 15% of people, however, do not improve with the first course of antibiotics and recurrence rates of up to 80% have been documented.
- metronidazole e.g., clindamycin, metronidazole
- Recurrence rates are increased with sexual activity with the same pre-post treatment partner and inconsistent condom use although estrogen-containing contraceptives decrease recurrence.
- Bacterial vaginosis is associated with up to a six-fold increase of HIV shedding.
- Bacterial vaginosis is a risk factor for viral shedding and herpes virus type-2 infection.
- Bacterial vaginosis may increase the risk infection or reactivation of HPV.
- Candida is yeast, a type of fungus.
- Yeast is usually present in the vagina in small numbers, and symptoms only appear with overgrowth.
- Candida can multiply when an imbalance occurs, such as when the normal acidity of the vagina changes or when hormonal balance changes.
- yeast infections may be a sign of more serious overarching health problem such as diabetes or a compromised immune system.
- Recurrent infections may also be due to use of antibiotic medications. About 5-8% of women experience four or more episodes per year, diagnosed as recurrent vulvovaginal candidiasis.
- Treatment for fungal infection can be topical or systemic.
- Topical antifungals such as miconazole (over the counter Monistat), are generally considered as first-line therapy for uncomplicated, superficial, relatively localized fungal infections due to their high efficacy and low potential for systemic adverse effects.
- Systemic antifungal agents are absorbed and delivered to the body through the blood stream.
- the oral route is usually the safest, the most economical, and the easiest route for systemic antifungal drugs.
- Oral fluconazole is available by prescription.
- Topical antifungal creams and suppositories have fewer side effects than oral a systemically by the body, and only exert a localized effect on the genital region.
- Antifungal pills affect the entire body, and side effects can include nausea, headaches, and abdominal pain.
- topical medications can be messy and uncomfortable, while pills are comparatively simple.
- Treatment using antifungal medication is ineffective in up to 20% of cases. Treatment for thrush is considered to have failed if the symptoms do not clear within 7-14 days.
- the incidence of resistance to antifungal agents may be increasing, with drug- resistant fungal strains becoming increasingly common causes of infection in high-risk patient groups such as HIV/AIDS patients. Accordingly, alternative antifungal strategies are being actively sought.
- Severe forms of infection are hard to treat, and frequently require more aggressive and long-term therapy, as is the case with chronic, recurrent cases. Additionally, incomplete treatments often result in drug resistant infections therefore full course of therapy should be adhered to.
- Oral antifungal medications carry the risk of significant side effects, and many patients are allergic to or intolerant of these drugs.
- Topical solutions can be messy and inconvenient.
- a device that leverages this rising technology could potentially gain rapid acceptance in specific use cases as well as broader support among the general population simply wishing to avoid exposure to additional medications.
- the present application is directed to medical devices and, more particularly, to vaginal light therapy devices, e.g., for treating bacterial and fungal infections, such as vaginitis, for treating pelvic inflammatory diseases, and/or for performing vaginal rejuvenation therapy, and to systems and methods for using such devices.
- vaginal light therapy devices e.g., for treating bacterial and fungal infections, such as vaginitis, for treating pelvic inflammatory diseases, and/or for performing vaginal rejuvenation therapy, and to systems and methods for using such devices.
- a light treatment device in accordance with an exemplary embodiment, includes an elongate member including a proximal end, a distal end sized for introduction into a vaginal canal, one or more light sources on the distal end, and an expandable member carried on the distal end and surrounding the one or more light sources.
- the expandable member may be configured to emit light outwardly from the one or more light sources at one or more wavelengths, e.g., within a range of germicidal light.
- the device may also include an inflator for expanding the expandable member from a contracted or delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
- a system for vaginal light therapy of a patient that includes a light treatment device comprising an elongate member including a proximal portion, a distal portion sized for introduction into a vaginal canal, one or more light sources, and an expandable member carried on the distal portion, the expandable member configured to emit light outwardly from the one or more light sources at one or more wavelengths within a range of germicidal light; and a controller comprising an inflator for expanding the expandable member from a delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
- a method for vaginal light therapy of a patient that includes inserting a distal end of an elongate light treatment device carrying an expandable member thereon into a vaginal canal with the expandable member in a contracted or delivery condition; expanding the expandable member within the vaginal canal; activating one or more light sources to emit light outwardly at one or more wavelengths, e.g., within a range of germicidal or other therapeutic light; and removing the device from the vaginal canal after treatment.
- the device may be used to deliver low-level germicidal light, e.g., to treat targeted pathogens, for example, to treat fungal or bacterial vaginitis.
- the device may be used to treat other conditions, such as pelvic inflammatory disease, and/or for performing vaginal rejuvenation therapy.
- a device for vaginal light therapy of a patient that includes a stiffening body at least partially surrounding a central region; a flexible membrane carried by the stiffening body across the central region; and one or more light sources carried by one or both of the membrane and stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
- a device for vaginal light therapy of a patient that includes a flexible membrane comprising a concave surface; a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient; and one or more light sources carried by one or both of the membrane and stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
- the device may carry a power source coupled to the one or more light sources, e.g., including a battery and/or processor, to deliver power to the one or more light sources when activated to emit light.
- the device may be connectable to an external power source and/or controller.
- an appendage may extend from one end of the device that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from the external power source.
- an external controller may be provided that is connectable to the appendage for delivering power to the one or more light sources, which may be activated manually or remotely by the patient.
- a system for vaginal light therapy of a patient that includes a light treatment device comprising a flexible membrane, a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient, one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light; and a controller connectable to the device for activating the one or more light sources to deliver light therapy within the vaginal canal.
- a light treatment device comprising a flexible membrane, a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient, one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light
- a controller connectable to the device for activating the one or more light sources to deliver light therapy within the vaginal canal.
- a device for vaginal light therapy of a patient that includes a malleable body sized for introduction into a vaginal canal of the patient; and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
- the device may carry a power source coupled to the one or more light sources, e.g., including a battery and/or processor, to deliver power to the one or more light sources when activated to emit light.
- the device may be connectable to an external power source and/or controller.
- an appendage may extend from one end of the device that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from the external power source.
- a method for vaginal light therapy of a patient includes providing a treatment device comprising an elongate member including a distal portion carrying an expandable member and one or more light sources; inserting the distal portion into a vaginal canal with the expandable member in a contracted condition; expanding the expandable member within the vaginal canal; activating the one or more light sources to emit light outwardly at one or more wavelengths within a range of germicidal light; and removing the device from the vaginal canal after treatment.
- FIG. 1 shows an exemplary embodiment of a device for vaginal light therapy of a patient including an expandable member carried on a distal end of an elongate member, and an inflator for selectively expanding the expandable member.
- FIGS. 2A and 2B are cross-sectional views of a subject’s anatomy showing the device of FIG. 1 being introduced into the subject’s vagina in a contracted condition (FIG.
- FIG. 2A expanded within the vagina for delivering light therapy
- FIG. 3 A shows another example of a device for vaginal light therapy of a patient including an expandable frame or stiffening body carrying a membrane and a plurality of LEDs.
- FIG. 3B shows the device of claim FIG. 3 A including an appendage for connecting the device to an external power source or controller.
- FIG. 4 is a cross-sectional view of a subject’s anatomy showing the device of FIGS. 3A and 3B introduced into the subject’s vagina for light therapy.
- references to “a compound” includes a plurality of such compounds and reference to “the polymer” includes reference to one or more polymers and equivalents thereof known to those skilled in the art, and so forth.
- FIG. 1 shows an exemplary embodiment of a vaginal therapy device 10 that includes a catheter, shaft, or other elongate member 20 including a proximal portion 22, a distal portion 24 carrying a balloon or other expandable member 30 and one or more light sources (not shown) for delivering light therapy to a subject, e.g., to treat bacterial or fungal infections, such as vaginitis, to treat pelvic inflammatory diseases, and/or to perform vaginal rejuvenation therapy, as described elsewhere herein.
- bacterial or fungal infections such as vaginitis
- pelvic inflammatory diseases e.ginitis
- the distal portion 24 may be substantially rigid, semi rigid, malleable, or flexible, while having sufficient column strength to insert the distal portion 24 into the subject’s vagina 90, e.g., until a distal tip 25 of the elongate member 20 is disposed adjacent the subject’s cervix 92.
- the proximal portion 22 may also be substantially rigid, semi-rigid, or flexible, e.g., having sufficient column strength to advance the distal portion 24 into the subject’s vagina while holding and/or manipulating the proximal portion 22.
- the proximal portion 22 may include a handle (not shown), e.g., extending from and/or otherwise attached to the proximal portion 22 to facilitate manipulation of the device 10 during use.
- the elongate member 20 may include one or more lumens, e.g., an inflation lumen (not shown) extending between the proximal and distal portions 22, 24 and communicating with an interior of the balloon 30 for delivering inflation media to expand the balloon 30 and/or for evacuating the inflation media to collapse the balloon 30.
- an inflator device 50 may be coupled to the proximal end 22 of the elongate member 20, e.g., via a hose or other line 52, for delivering inflation media into and/or evacuating inflation media from the balloon 30 via the inflation lumen.
- the proximal portion 22 may include a port 23 communicating with the inflation lumen that includes a connector for removably connecting the hose 52 to the proximal portion 22.
- the elongate member 20 may include one or more additional lumens, e.g., carrying one or more wires, optical fibers, and the like (not shown) for delivering power or light to the one or more light sources on the distal portion 24.
- the inflator may be integrated into the shaft 20, e.g., within a handle on the proximal portion 22 (not shown).
- the device 10 may include a rigid or flexible “wand” carrying an uninflated, stretchable balloon 30 covering a desired length along the distal portion 24, e.g., as shown in FIG. 1 and 2 A.
- the balloon 30 may include a proximal end 32 attached to the shaft 20, and an enclosed distal end 34 that extends over the distal tip 25.
- the balloon may include an annular distal end (not shown) attached to the distal portion 24, e.g., adjacent the distal tip 25.
- FIG. 2B shows the balloon 30 inflated, e.g., with air or other fluid, as described further elsewhere herein.
- One or more LEDs, optic fibers, or other light sources may be mounted in the wall and/or otherwise positioned or carried on the distal portion 10 of the shaft 20 over the length covered by the balloon 30.
- the light source(s) may be activated to irradiate the vaginal wall through the inflated balloon 30, e.g., similar to the devices disclosed in U.S. Patent No. 10,004,918, U.S. Publication No. 2018/ 0361170, and International Publication No. WO 2021/ 071973, the entire disclosures of which are expressly incorporated by reference herein.
- the balloon 30 may be (i) thin walled and made of a material to allow light to pass without significant attenuation, e.g., material that is transparent to at least the wavelength(s) of light emitted by the light source, and (ii) inflated with a low-attenuation material such as a compressible fluid, such as air or carbon dioxide.
- a low-attenuation material such as a compressible fluid, such as air or carbon dioxide.
- one or more light sources may be mounted, embedded in, or otherwise fixed to the wall of the balloon 30.
- a plurality of LEDs and the like may be attached to the wall of the balloon 30 that are spaced apart from one another to transmit light radially outwardly from the balloon 30.
- a plurality of light fibers may be embedded in or otherwise attached to the wall of the balloon 30.
- one or more light sources may be provided on the proximal portion 22 and/or on the inflator device 50 that may communicate light to the light fibers, e.g., via fibers within a lumen of the shaft 20 (not shown), with ends of the fibers arranged on the balloon 30 transmitting the light radially outwardly from the balloon 30.
- an indicator or controller may be provided to inform the operator of the status of the balloon 30, e.g., based on the inflating volume and/or pressure.
- the inflator device 50 may include a manual or motorized pump, a syringe, and the like (not shown), that may be coupled to a valve, e.g., on the connector 23 on the proximal portion 22 of the shaft 20.
- the inflator device 50 may be configured to deliver inflation media through the inflation lumen of the shaft 20 into the interior of the balloon 30, e.g., to deliver a predetermined volume of inflation media to inflate the balloon 30 to a desired size.
- the inflator device 50 may monitor the pressure of the inflation media being delivered, e.g., to ensure a maximum pressure is not exceeded.
- one or more actuators may be provided on the proximal portion 22, e.g., on a handle attached to the proximal portion 22, which may be activated by the user to activate/deactivate the inflator device 50 and/or turn the light source(s) on and off, as desired.
- a compressible gas or other fluid may be delivered via the inflator device 50 to expand the balloon 30 and dilate and/or otherwise shape the subject’s anatomy surrounding the vagina 90 before light delivery, e.g., to dilate the vagina and/or otherwise expose tissue surfaces for treatment.
- the compressible fluid and elastic balloon may also allow the balloon 30 to conform at least somewhat to the user’s anatomy, e.g., to minimize gaps between the balloon and vaginal wall.
- Exemplary gases may include carbon dioxide or other biocompatible gas (particularly for applications where rupture of the balloon 30 may expose the fluid to the subject’s vascular system). Assuming use of an ideal gas, the inflated volume may be inversely proportional to the pressure to which the balloon 30 is inflated.
- a manual inflator device may include an actuator and visual indicia (not shown) to identify the volume being delivered, or a motorized inflator device may deliver fluid until the predetermined volume is delivered and then automatically shut off.
- external imaging e.g., ultrasound, may be used to monitor inflation of the balloon 30 to confirm when a desired size and/or shape are attained.
- valves may be provided within the shaft 20 that are coupled in series such that, once desired pressure, e.g., five psi is achieved, the inflator device 50 may automatically shut off.
- the device 10 may include a relief valve (not shown) to release excess pressure and/or prevent over-inflation of the balloon 30 during use.
- the balloon 30 may be made of an inelastic material to provide a balloon with a single volume and/or shape once inflated (i.e., the balloon does not expand appreciably with increased pressure once fully inflated).
- the balloon 30 may have a desired shape configured to dilate and/or otherwise shape the vaginal wall, e.g., to enhance exposure to the light transmitted by the device.
- the material may be reasonably strong with low light attenuation, such as cellophane, for example.
- the balloon 30 may be inflated to a pressure that provides full expansion of the balloon 30 within any typical vaginal cavity, e.g., using a compressible fluid, such as carbon dioxide, or an incompressible fluid, that is non-attenuating to the light transmitted by the light source(s).
- a compressible fluid such as carbon dioxide, or an incompressible fluid
- no indicator to inform the operator of the balloon volume may be required if incompressible fluid is used given the fixed shape of the balloon.
- one or more LEDs or other light sources may be activated to emit light from the shaft 20 through the and balloon wall to the vaginal wall.
- compressible fluid may include carbon dioxide, nitrogen, and the like, e.g., in case the balloon ruptures and the gas enters the blood stream.
- the stiff balloon material may be a thicker, more-robust material that substantially attenuates light.
- one or more LEDs or other light sources may be mounted on or in the balloon wall.
- an incompressible fluid such as water, may be used to inflate the balloon.
- the devices described herein may be used by an individual on their own, e.g., at home or other non-medical setting.
- the devices may be operated by a medical professional, e.g., in a doctor’s office, hospital, or other location, to provide one or more treatments delivering vaginal light therapy of a patient.
- the distal portion 24 of the device 10 (carrying the balloon 30 and one or more light sources) may be inserted into a vaginal canal 90 with the balloon 30 in a contracted condition.
- the balloon 30 may be expanded, e.g., by connecting the hose 52 of the inflator device to the proximal portion 22 and delivering inflation media, e.g., a predetermined volume of biocompatible fluid.
- positioning and/or inflation of the balloon 30 may be monitored by the operator, e.g., using ultrasound or other external imaging, e.g., to ensure the balloon 30 is inflated to a desired size and/or shape.
- the one or more light sources may then be activated to emit light outwardly at one or more wavelengths, e.g., within a range of non-UV or other suitable germicidal light.
- the balloon 30 may be deflated, and the device 10 removed from the vaginal canal 90 after treatment.
- the device 10 may sterilized and/or otherwise cleaned for subsequent reuse, or may be discarded as a single-use device.
- FIGS. 3 A and 3B another embodiment of a vaginal light therapy device 110 is shown that is sized and/or shaped for insertion into a subject’s vagina 90 (e.g., as shown in FIG. 4).
- the device 110 includes a supporting frame or body 120 carrying a membrane 130 and one or more light sources, e.g., a plurality of LEDs 140 mounted on or within one or both of the body 120 and membrane 130.
- the light source(s) 140 may be configured to emanate light from one or both surfaces of the body 120 and/or membrane 130, e.g., at one or more wavelengths within a range of germicidal light, as described further elsewhere herein.
- the stiffening body 120 may extend at least partially around a perimeter of the membrane 130, e.g., having an annular shape around the entire perimeter, as shown, or alternatively, having a “C” or other shape extending only partially around the perimeter (not shown).
- the stiffening body 120 may be biased to a desired shape, e.g., to support the membrane 130 extending across a central region within the stiffening body 120, yet may be deflectable and/or deformable to allow the device 110 to be compressed for introduction.
- the membrane 130 may be biased to a domed or other shape extending out of a plane generally defined by the stiffening body 120, e.g., defining an inner concave surface 132a and an outer convex surface 132b, which may be shaped to be placed against or adjacent desired vaginal surfaces.
- One or more light sources 140 may be provided on or within one or both surfaces 132, e.g., to transmit light outwardly from the membrane 130 in all directions.
- the light sources 140 may include individual LEDs or optic fibers extending from a source LED spaced apart from one another or otherwise distributed in a desired configuration relative to the membrane 130.
- the membrane 130 may be translucent or transparent to the frequency range of light transmitted by the light source(s) 140, e.g., such that light may pass through the membrane 130 if the light sources are mounted on only one surface or are located within the membrane 130.
- the membrane may include multiple layers of material, e.g., inner and outer membranes (not shown), with one or more light sources mounted or otherwise located between the membrane layers.
- One or both membranes may be translucent or transparent to the frequency range of light transmitted by the light source(s).
- a plurality of light sources may also be mounted on or within the stiffening body 120, if desired.
- the stiffening body 120 and membrane 130 may be formed separately and permanently attached together or may be integrally formed from the same material, e.g., by molding, casting, and the like.
- the body 120 and membrane 130 may be formed from elastomeric or other flexible, biocompatible material, e.g., silicone, that may be formed to a desired shape.
- the stiffening body 120 may include one or more additional supports, e.g., wires, bands, and the like (not shown) embedded within and/or attached to one or more external surfaces of the body 120, e.g., to provide additional support and/or bias.
- the stiffening body 120 may have sufficient bias to allow the device 110 to be rolled, folded, or otherwise compressed to a contracted condition to facilitate introduction, yet resiliently return towards an expanded shape when released to open the membrane 130 within the vaginal cavity 90, as shown in FIG. 4.
- the membrane 130 may have sufficient elasticity to be compressed when the device 110 is rolled or folded, yet resiliently expand to the domed or other shape when released, e.g., to contact and, optionally, to at least partially dilate surrounding tissue.
- the device 110 may include an appendage 150, which may be permanently and/or integrally formed with the stiffening body 120 or membrane 130, or may be removably connected to the device 110, e.g., by a connector (not shown) on the body 120.
- the appendage 150 may include one or more leads 152 embedded within or otherwise carried by the appendage 150, which may be coupled to the light source(s) 140, e.g., to provide power to and/or otherwise operate the light source(s) 140.
- the appendage 150 may be connected or connectable to an external power supply or controller 160, which may selectively activate the light source(s) 140 during use.
- the light sources 140 are optic fibers
- the leads 152 may include optic fibers that may be optically coupled to the fibers within the device 110, and one or more LEDs or other light sources may be provided within the controller 160.
- a connector may be provided on one or both ends of the appendage 150, e.g., a first end that connects to the device 110 and a second end that connects to the power supply/controller 160. Alternatively, one or both ends may be permanently connected to the device 110 or the controller 160.
- the appendage 150 may include one or more additional LEDs or other light sources (not shown), e.g., along an inner curve, to radiate the introitus and vulvar regions of the patient.
- the appendage 150 may be biased to a curved shape yet may be sufficiently flexible to facilitate introduction and/or removal of the device 110.
- one end of the stiffening body may include an integral extension that provides the appendage 150.
- the appendage 150 may simply be a cable or other tether for connecting the device 110 to the power sour ce/contr oiler 160.
- the device 110 may include one or more of a controller, e.g., for operating the light source(s) 140 in a desired manner, a battery or other power source, and/or a wireless communications interface (not shown) carried on or in the device 110.
- such components may be embedded in the membrane 120, mounted on the stiffening body 130, and/or carried on an appendage 150 extending from the stiffening body 120
- the device 110 may be rolled, folded, or otherwise compressed into a contracted configuration, e.g., manually or using an insertion tool that constrains the device 110, a 90.
- the device 110 may be released, whereupon the stiffening body 120 may resiliently deploy into an expanded configuration, which may position the membrane 130, and consequently, the light source(s) 140 adjacent desired tissue regions of the vagina 90 and/or vaginal canal.
- the light source(s) 140 may then be activated to treat an infection and then removed by the user, similar to other embodiments herein and in the applications incorporated by reference herein.
- the device 110 may have a length that is greater than its width, e.g., such that a first end of the device 110 may be positioned against or adjacent the cervix 92 while a second opposite end is positioned within the entrance to the vaginal cavity, e.g., such the appendage 150 extends from the vagina 90 (if provided).
- the first end may have a curved and/or concave shape, e.g., to conform to the shape of the cervix 92, which may facilitate proper positioning of the device 110.
- the second end may include one or more features, e.g., tabs or holds, which may facilitate gripping the device 110 during introduction and/or removal after use.
- a device for vaginal light therapy of a patient may be provided that includes a malleable body sized for introduction into a vaginal canal of the patient, and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
- the body may include an internal power source and/or controller, which may be used to selectively activate the light source(s).
- an appendage may extend from one end of the body that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from an external power source and/or controller, similar to other embodiments herein.
- the malleable material of the body may be manually manipulated to a desired shape, which may facilitate introduction and/or position of the device within the user’s vaginal canal for light therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Devices, systems, and methods are provided for vaginal light therapy of a subject using a device carrying an expandable member and one or more light sources. A distal end of the device carrying the expandable member thereon is introduced a vaginal canal with the expandable member in a contracted condition, the expandable member is expanded within the vaginal canal, the one or more light sources are activated to emit light outwardly at one or more wavelengths within a range of germicidal or other therapeutic light; and the device is removed from the vaginal canal after treatment.
Description
VAGINAL LIGHT THERAPY DEVICES AND METHODS FOR USING THEM
RELATED APPLICATION DATA
The present application claims benefit of co-pending U.S. provisional applications 63/012, 700 and 63/012,708, both filed April 20, 2020, and is a continuation-in-part of U.S application Serial No. 17/001,609, filed August 24, 2020, the entire disclosures of which are expressly incorporated by reference herein.
FIELD OF THE INVENTION
The present application generally relates to medical devices and, more particularly, to vaginal light therapy devices, e.g., for treatment of bacterial and fungal infections, and to systems and methods for using such devices.
BACKGROUND
Vaginitis is characterized by inflammation of the vagina that results in discharge, itching and pain. The cause is usually due to a change in the normal balance of vaginal bacteria or an infection. As many as 75% of the female population experience bacterial or fungal infection within their vagina at least once during their lifetime. The symptoms range from mucus-like discharge, itching, aching, pain during intercourse to odor. The vaginal infections often have multiple causes that present challenging cases for treatment.
It is critical to have a balance between naturally occurring yeast and bacteria. It is when the system is out of balance or other types of bacteria or yeast are present within the environment does one end up with vaginitis. Sometimes the reduction in good bacteria due to use of antibiotic allows for a propagation of yeast, typically Candida albicans resulting in yeast infection. Further, either a change in pH balance or introduction of foreign bacteria in the vagina leads to infectious vaginitis. Physical factors that contribute to the development of an infection include the following: constantly wet vulva due to tight clothing, chemicals coming in contact with the vagina via scented tampons, antibiotics, birth control pills, or a diet favoring refined sugar and yeast.
Bacterial vaginosis also known as vaginal bacteriosis or Gardnerella Vaginitis is a disease of the vagina caused by excessive bacteria growth. Common symptoms include increased vaginal discharge that often smells fishlike. The discharge is usually white or gray in color. Burning with urination may also occur. Itching is uncommon. Occasionally
there may be no symptoms. Having bacterial vaginosis increases the risk of infection by a number of other sexually transmitted infections including HIV/AIDS. It also increases the risk of early delivery among pregnant women. Bacterial vaginosis is caused by an imbalance of the naturally occurring bacteria in the vagina. Diagnosis is suspected based on the symptoms and may be verified by testing the vaginal discharge and finding a higher than normal vaginal pH and large numbers of bacteria.
Bacterial vaginosis is often confused with a vaginal yeast infection. Usually treatment is through the use of antibiotics. Bacterial vaginosis is the most common vaginal infection in women of reproductive age. The percentage of women affected at any given time varies but can be as high as 35%. Antibiotics, administered either orally (e.g., metronidazole) or vaginally (e.g., clindamycin, metronidazole) are effective in treatment. About 10% to 15% of people, however, do not improve with the first course of antibiotics and recurrence rates of up to 80% have been documented. Recurrence rates are increased with sexual activity with the same pre-post treatment partner and inconsistent condom use although estrogen-containing contraceptives decrease recurrence. There is evidence of an association between bacterial vaginosis and increased rates of sexually transmitted infections such as HIV/AIDS. Bacterial vaginosis is associated with up to a six-fold increase of HIV shedding. There is also a correlation between the absence of vaginal lactobacilli and infection of Neisseria gonorrhoeae and Chlamydia trachomatis. Bacterial vaginosis is a risk factor for viral shedding and herpes virus type-2 infection. Bacterial vaginosis may increase the risk infection or reactivation of HPV.
Candidiasis, more commonly referred to as a yeast infection, is most commonly caused by an overgrowth of a fungus called Candida albicans in the vagina. Candida is yeast, a type of fungus. Yeast is usually present in the vagina in small numbers, and symptoms only appear with overgrowth. Candida can multiply when an imbalance occurs, such as when the normal acidity of the vagina changes or when hormonal balance changes. Frequently occurring yeast infections may be a sign of more serious overarching health problem such as diabetes or a compromised immune system. Recurrent infections may also be due to use of antibiotic medications. About 5-8% of women experience four or more episodes per year, diagnosed as recurrent vulvovaginal candidiasis. About 75% of all premenopausal women develop thrush at some point in their lives. With the introduction of over-the-counter medications for home treatment of yeast infections, many women elect to
self-diagnose and self-medicate, indicating that the true incidence of yeast infections annually may be significantly under reported.
In comparison to antibacterial therapy, antifungal treatment is limited to a very small number of drug substances. Treatment for fungal infection can be topical or systemic. Topical antifungals, such as miconazole (over the counter Monistat), are generally considered as first-line therapy for uncomplicated, superficial, relatively localized fungal infections due to their high efficacy and low potential for systemic adverse effects.
Systemic antifungal agents are absorbed and delivered to the body through the blood stream. The oral route is usually the safest, the most economical, and the easiest route for systemic antifungal drugs. Oral fluconazole is available by prescription.
Topical antifungal creams and suppositories have fewer side effects than oral a systemically by the body, and only exert a localized effect on the genital region. Antifungal pills affect the entire body, and side effects can include nausea, headaches, and abdominal pain. However, topical medications can be messy and uncomfortable, while pills are comparatively simple. Treatment using antifungal medication is ineffective in up to 20% of cases. Treatment for thrush is considered to have failed if the symptoms do not clear within 7-14 days. In addition, the incidence of resistance to antifungal agents may be increasing, with drug- resistant fungal strains becoming increasingly common causes of infection in high-risk patient groups such as HIV/AIDS patients. Accordingly, alternative antifungal strategies are being actively sought.
Severe forms of infection are hard to treat, and frequently require more aggressive and long-term therapy, as is the case with chronic, recurrent cases. Additionally, incomplete treatments often result in drug resistant infections therefore full course of therapy should be adhered to.
Although light therapy treatment of various bacterial, fungal or viral infection is generally known, a treatment of such infections is generally achieved through chemical or drug therapies. A use of such therapies affects an internal functioning of the vagina and uterus as the chemicals used in the form of paste or gel or liquid result in unwanted chemical reactions that are harsh or result in various complications.
Oral antifungal medications carry the risk of significant side effects, and many patients are allergic to or intolerant of these drugs. Topical solutions can be messy and inconvenient. There are no existing products for the treatment of yeast infections without
also requiring medication. Hence there is a need for a product that allows for the treatment of yeast and bacterial infections quickly and simply without systemic effects. With the continued and accelerating emergence of antibiotic-resistant microorganisms, there is burgeoning interest and investment in light therapy. A device that leverages this rising technology could potentially gain rapid acceptance in specific use cases as well as broader support among the general population simply wishing to avoid exposure to additional medications.
In the view of the foregoing, improved devices and methods for treating intravaginal infections and/or other conditions would be useful.
SUMMARY
The present application is directed to medical devices and, more particularly, to vaginal light therapy devices, e.g., for treating bacterial and fungal infections, such as vaginitis, for treating pelvic inflammatory diseases, and/or for performing vaginal rejuvenation therapy, and to systems and methods for using such devices.
In accordance with an exemplary embodiment, a light treatment device is provided that includes an elongate member including a proximal end, a distal end sized for introduction into a vaginal canal, one or more light sources on the distal end, and an expandable member carried on the distal end and surrounding the one or more light sources. The expandable member may be configured to emit light outwardly from the one or more light sources at one or more wavelengths, e.g., within a range of germicidal light. Optionally, the device may also include an inflator for expanding the expandable member from a contracted or delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
In accordance with still another embodiment, a system is provided for vaginal light therapy of a patient that includes a light treatment device comprising an elongate member including a proximal portion, a distal portion sized for introduction into a vaginal canal, one or more light sources, and an expandable member carried on the distal portion, the expandable member configured to emit light outwardly from the one or more light sources at one or more wavelengths within a range of germicidal light; and a controller comprising an inflator for expanding the expandable member from a delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
In accordance with another embodiment, a method is provided for vaginal light therapy of a patient that includes inserting a distal end of an elongate light treatment device carrying an expandable member thereon into a vaginal canal with the expandable member in a contracted or delivery condition; expanding the expandable member within the vaginal canal; activating one or more light sources to emit light outwardly at one or more wavelengths, e.g., within a range of germicidal or other therapeutic light; and removing the device from the vaginal canal after treatment. For example, the device may be used to deliver low-level germicidal light, e.g., to treat targeted pathogens, for example, to treat fungal or bacterial vaginitis. Alternatively, the device may be used to treat other conditions, such as pelvic inflammatory disease, and/or for performing vaginal rejuvenation therapy.
In accordance with still another embodiment, a device is provided for vaginal light therapy of a patient that includes a stiffening body at least partially surrounding a central region; a flexible membrane carried by the stiffening body across the central region; and one or more light sources carried by one or both of the membrane and stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
In accordance with yet another embodiment, a device is provided for vaginal light therapy of a patient that includes a flexible membrane comprising a concave surface; a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient; and one or more light sources carried by one or both of the membrane and stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
Optionally, the device may carry a power source coupled to the one or more light sources, e.g., including a battery and/or processor, to deliver power to the one or more light sources when activated to emit light. Alternatively, the device may be connectable to an external power source and/or controller. For example, an appendage may extend from one end of the device that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from the external power source. For example, an external controller may be provided that is connectable to the appendage for delivering power to the one or more light sources, which may be activated manually or remotely by the patient.
In accordance with still another embodiment, a system is provided for vaginal light therapy of a patient that includes a light treatment device comprising a flexible membrane, a
stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient, one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light; and a controller connectable to the device for activating the one or more light sources to deliver light therapy within the vaginal canal.
In accordance with another embodiment, a device is provided for vaginal light therapy of a patient that includes a malleable body sized for introduction into a vaginal canal of the patient; and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light. Optionally, the device may carry a power source coupled to the one or more light sources, e.g., including a battery and/or processor, to deliver power to the one or more light sources when activated to emit light. Alternatively, the device may be connectable to an external power source and/or controller. For example, an appendage may extend from one end of the device that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from the external power source.
In accordance with yet another embodiment, a method is provided for vaginal light therapy of a patient that includes providing a treatment device comprising an elongate member including a distal portion carrying an expandable member and one or more light sources; inserting the distal portion into a vaginal canal with the expandable member in a contracted condition; expanding the expandable member within the vaginal canal; activating the one or more light sources to emit light outwardly at one or more wavelengths within a range of germicidal light; and removing the device from the vaginal canal after treatment.
Other aspects and features of the present invention will become apparent from consideration of the following description taken in conjunction with the accompanying drawings.
BRIF.F DESCRIPTION OF THE DRAWINGS The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features and design elements of the drawings are not to-scale. On the contrary, the dimensions of the various features and design elements are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures:
FIG. 1 shows an exemplary embodiment of a device for vaginal light therapy of a patient including an expandable member carried on a distal end of an elongate member, and an inflator for selectively expanding the expandable member.
FIGS. 2A and 2B are cross-sectional views of a subject’s anatomy showing the device of FIG. 1 being introduced into the subject’s vagina in a contracted condition (FIG.
2 A) and expanded within the vagina for delivering light therapy (FIG. 2B).
FIG. 3 A shows another example of a device for vaginal light therapy of a patient including an expandable frame or stiffening body carrying a membrane and a plurality of LEDs.
FIG. 3B shows the device of claim FIG. 3 A including an appendage for connecting the device to an external power source or controller.
FIG. 4 is a cross-sectional view of a subject’s anatomy showing the device of FIGS. 3A and 3B introduced into the subject’s vagina for light therapy.
DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS
Before the exemplary embodiments are described, it is to be understood that the invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, some potential and exemplary methods and materials are now described.
It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” a include plural referents unless the context clearly dictates otherwise.
Thus, for example, reference to “a compound” includes a plurality of such compounds and reference to “the polymer” includes reference to one or more polymers and equivalents thereof known to those skilled in the art, and so forth.
Turning to the drawings, FIG. 1 shows an exemplary embodiment of a vaginal therapy device 10 that includes a catheter, shaft, or other elongate member 20 including a proximal portion 22, a distal portion 24 carrying a balloon or other expandable member 30
and one or more light sources (not shown) for delivering light therapy to a subject, e.g., to treat bacterial or fungal infections, such as vaginitis, to treat pelvic inflammatory diseases, and/or to perform vaginal rejuvenation therapy, as described elsewhere herein.
The distal por vagina 90 with the balloon 30 in a contracted or delivery condition, e.g., as shown in FIG. 2A. In an exemplary embodiment, the distal portion 24 may be substantially rigid, semi rigid, malleable, or flexible, while having sufficient column strength to insert the distal portion 24 into the subject’s vagina 90, e.g., until a distal tip 25 of the elongate member 20 is disposed adjacent the subject’s cervix 92. Optionally, the proximal portion 22 may also be substantially rigid, semi-rigid, or flexible, e.g., having sufficient column strength to advance the distal portion 24 into the subject’s vagina while holding and/or manipulating the proximal portion 22. Optionally, the proximal portion 22 may include a handle (not shown), e.g., extending from and/or otherwise attached to the proximal portion 22 to facilitate manipulation of the device 10 during use.
The elongate member 20 may include one or more lumens, e.g., an inflation lumen (not shown) extending between the proximal and distal portions 22, 24 and communicating with an interior of the balloon 30 for delivering inflation media to expand the balloon 30 and/or for evacuating the inflation media to collapse the balloon 30. For example, as shown in FIG. 1, an inflator device 50 may be coupled to the proximal end 22 of the elongate member 20, e.g., via a hose or other line 52, for delivering inflation media into and/or evacuating inflation media from the balloon 30 via the inflation lumen. For example, the proximal portion 22 may include a port 23 communicating with the inflation lumen that includes a connector for removably connecting the hose 52 to the proximal portion 22. In addition, the elongate member 20 may include one or more additional lumens, e.g., carrying one or more wires, optical fibers, and the like (not shown) for delivering power or light to the one or more light sources on the distal portion 24. Alternatively, the inflator may be integrated into the shaft 20, e.g., within a handle on the proximal portion 22 (not shown).
In an exemplary embodiment, the device 10 may include a rigid or flexible “wand” carrying an uninflated, stretchable balloon 30 covering a desired length along the distal portion 24, e.g., as shown in FIG. 1 and 2 A. For example, as shown in FIG. 1, the balloon 30 may include a proximal end 32 attached to the shaft 20, and an enclosed distal end 34 that extends over the distal tip 25. Alternatively, the balloon may include an annular distal end (not shown) attached to the distal portion 24, e.g., adjacent the distal tip 25. FIG. 2B
shows the balloon 30 inflated, e.g., with air or other fluid, as described further elsewhere herein. One or more LEDs, optic fibers, or other light sources (not shown) may be mounted in the wall and/or otherwise positioned or carried on the distal portion 10 of the shaft 20 over the length covered by the balloon 30. Once the distal portion 24 is inserted and the balloon 30 is inflated, the light source(s) may be activated to irradiate the vaginal wall through the inflated balloon 30, e.g., similar to the devices disclosed in U.S. Patent No. 10,004,918, U.S. Publication No. 2018/ 0361170, and International Publication No. WO 2021/ 071973, the entire disclosures of which are expressly incorporated by reference herein.
In this configuration, for light to travel effectively from the distal portion 24 to the vaginal wall, the balloon 30 may be (i) thin walled and made of a material to allow light to pass without significant attenuation, e.g., material that is transparent to at least the wavelength(s) of light emitted by the light source, and (ii) inflated with a low-attenuation material such as a compressible fluid, such as air or carbon dioxide. Alternatively, one or more light sources may be mounted, embedded in, or otherwise fixed to the wall of the balloon 30. For example, a plurality of LEDs and the like (not shown) may be attached to the wall of the balloon 30 that are spaced apart from one another to transmit light radially outwardly from the balloon 30. Alternatively, a plurality of light fibers (not shown) may be embedded in or otherwise attached to the wall of the balloon 30. In this alternative, one or more light sources (also not shown) may be provided on the proximal portion 22 and/or on the inflator device 50 that may communicate light to the light fibers, e.g., via fibers within a lumen of the shaft 20 (not shown), with ends of the fibers arranged on the balloon 30 transmitting the light radially outwardly from the balloon 30.
Optionally, because the operator cannot see the balloon 30 once inserted into the vagina 90, an indicator or controller (not shown) may be provided to inform the operator of the status of the balloon 30, e.g., based on the inflating volume and/or pressure. For example, the inflator device 50 may include a manual or motorized pump, a syringe, and the like (not shown), that may be coupled to a valve, e.g., on the connector 23 on the proximal portion 22 of the shaft 20. The inflator device 50 may be configured to deliver inflation media through the inflation lumen of the shaft 20 into the interior of the balloon 30, e.g., to deliver a predetermined volume of inflation media to inflate the balloon 30 to a desired size. In addition or alternatively, the inflator device 50 may monitor the pressure of the inflation media being delivered, e.g., to ensure a maximum pressure is not exceeded. In addition or
alternatively, one or more actuators (not shown) may be provided on the proximal portion 22, e.g., on a handle attached to the proximal portion 22, which may be activated by the user to activate/deactivate the inflator device 50 and/or turn the light source(s) on and off, as desired.
For example, a compressible gas or other fluid may be delivered via the inflator device 50 to expand the balloon 30 and dilate and/or otherwise shape the subject’s anatomy surrounding the vagina 90 before light delivery, e.g., to dilate the vagina and/or otherwise expose tissue surfaces for treatment. The compressible fluid and elastic balloon may also allow the balloon 30 to conform at least somewhat to the user’s anatomy, e.g., to minimize gaps between the balloon and vaginal wall. Exemplary gases may include carbon dioxide or other biocompatible gas (particularly for applications where rupture of the balloon 30 may expose the fluid to the subject’s vascular system). Assuming use of an ideal gas, the inflated volume may be inversely proportional to the pressure to which the balloon 30 is inflated. Since the amount of pressure to achieve a desired volume may vary significantly from one woman’s vagina to another, depending on such factors as body weight, pelvic floor dimensions, muscle tone, number of prior pregnancies, etc., inflating the balloon 30 to a predetermined volume may ensure proper inflation independent of the anatomy encountered. A manual inflator device may include an actuator and visual indicia (not shown) to identify the volume being delivered, or a motorized inflator device may deliver fluid until the predetermined volume is delivered and then automatically shut off. In addition or alternatively, external imaging, e.g., ultrasound, may be used to monitor inflation of the balloon 30 to confirm when a desired size and/or shape are attained.
Alternatively, multiple valves may be provided within the shaft 20 that are coupled in series such that, once desired pressure, e.g., five psi is achieved, the inflator device 50 may automatically shut off. In addition or alternatively, the device 10 may include a relief valve (not shown) to release excess pressure and/or prevent over-inflation of the balloon 30 during use.
In another embodiment, the balloon 30 may be made of an inelastic material to provide a balloon with a single volume and/or shape once inflated (i.e., the balloon does not expand appreciably with increased pressure once fully inflated). For example, the balloon 30 may have a desired shape configured to dilate and/or otherwise shape the vaginal wall, e.g., to enhance exposure to the light transmitted by the device. The material may be reasonably strong with low light attenuation, such as cellophane, for example.
In this embodiment, the balloon 30 may be inflated to a pressure that provides full expansion of the balloon 30 within any typical vaginal cavity, e.g., using a compressible fluid, such as carbon dioxide, or an incompressible fluid, that is non-attenuating to the light transmitted by the light source(s). In this alternative, no indicator to inform the operator of the balloon volume may be required if incompressible fluid is used given the fixed shape of the balloon. As in the earlier embodiment, one or more LEDs or other light sources may be activated to emit light from the shaft 20 through the and balloon wall to the vaginal wall. Examples of compressible fluid may include carbon dioxide, nitrogen, and the like, e.g., in case the balloon ruptures and the gas enters the blood stream.
In another embodiment, the stiff balloon material may be a thicker, more-robust material that substantially attenuates light. In such a configuration, one or more LEDs or other light sources may be mounted on or in the balloon wall. In this configuration, an incompressible fluid, such as water, may be used to inflate the balloon.
The devices described herein may be used by an individual on their own, e.g., at home or other non-medical setting. Alternatively, the devices may be operated by a medical professional, e.g., in a doctor’s office, hospital, or other location, to provide one or more treatments delivering vaginal light therapy of a patient.
For example, initially, as shown in FIG. 2A, the distal portion 24 of the device 10 (carrying the balloon 30 and one or more light sources) may be inserted into a vaginal canal 90 with the balloon 30 in a contracted condition. Once positioned as desired, e.g., with the distal tip 25 against or immediately adjacent the cervix 92, the balloon 30 may be expanded, e.g., by connecting the hose 52 of the inflator device to the proximal portion 22 and delivering inflation media, e.g., a predetermined volume of biocompatible fluid. Optionally, particularly if the balloon 30 is formed from elastic material, positioning and/or inflation of the balloon 30 may be monitored by the operator, e.g., using ultrasound or other external imaging, e.g., to ensure the balloon 30 is inflated to a desired size and/or shape. The one or more light sources may then be activated to emit light outwardly at one or more wavelengths, e.g., within a range of non-UV or other suitable germicidal light. Upon completion of a desired treatment, the balloon 30 may be deflated, and the device 10 removed from the vaginal canal 90 after treatment. The device 10 may sterilized and/or otherwise cleaned for subsequent reuse, or may be discarded as a single-use device.
Turning to FIGS. 3 A and 3B, another embodiment of a vaginal light therapy device 110 is shown that is sized and/or shaped for insertion into a subject’s vagina 90 (e.g., as
shown in FIG. 4). Generally, the device 110 includes a supporting frame or body 120 carrying a membrane 130 and one or more light sources, e.g., a plurality of LEDs 140 mounted on or within one or both of the body 120 and membrane 130. The light source(s) 140 may be configured to emanate light from one or both surfaces of the body 120 and/or membrane 130, e.g., at one or more wavelengths within a range of germicidal light, as described further elsewhere herein.
The stiffening body 120 may extend at least partially around a perimeter of the membrane 130, e.g., having an annular shape around the entire perimeter, as shown, or alternatively, having a “C” or other shape extending only partially around the perimeter (not shown). The stiffening body 120 may be biased to a desired shape, e.g., to support the membrane 130 extending across a central region within the stiffening body 120, yet may be deflectable and/or deformable to allow the device 110 to be compressed for introduction.
The membrane 130 may be biased to a domed or other shape extending out of a plane generally defined by the stiffening body 120, e.g., defining an inner concave surface 132a and an outer convex surface 132b, which may be shaped to be placed against or adjacent desired vaginal surfaces. One or more light sources 140 may be provided on or within one or both surfaces 132, e.g., to transmit light outwardly from the membrane 130 in all directions. For example, the light sources 140 may include individual LEDs or optic fibers extending from a source LED spaced apart from one another or otherwise distributed in a desired configuration relative to the membrane 130. Optionally, the membrane 130 may be translucent or transparent to the frequency range of light transmitted by the light source(s) 140, e.g., such that light may pass through the membrane 130 if the light sources are mounted on only one surface or are located within the membrane 130.
In an alternative embodiment, the membrane may include multiple layers of material, e.g., inner and outer membranes (not shown), with one or more light sources mounted or otherwise located between the membrane layers. One or both membranes may be translucent or transparent to the frequency range of light transmitted by the light source(s). In addition or alternatively, a plurality of light sources may also be mounted on or within the stiffening body 120, if desired.
The stiffening body 120 and membrane 130 may be formed separately and permanently attached together or may be integrally formed from the same material, e.g., by molding, casting, and the like. For example, the body 120 and membrane 130 may be formed from elastomeric or other flexible, biocompatible material, e.g., silicone, that may
be formed to a desired shape. Optionally, the stiffening body 120 may include one or more additional supports, e.g., wires, bands, and the like (not shown) embedded within and/or attached to one or more external surfaces of the body 120, e.g., to provide additional support and/or bias. For example, the stiffening body 120 may have sufficient bias to allow the device 110 to be rolled, folded, or otherwise compressed to a contracted condition to facilitate introduction, yet resiliently return towards an expanded shape when released to open the membrane 130 within the vaginal cavity 90, as shown in FIG. 4. The membrane 130 may have sufficient elasticity to be compressed when the device 110 is rolled or folded, yet resiliently expand to the domed or other shape when released, e.g., to contact and, optionally, to at least partially dilate surrounding tissue.
Fungal and bacterial infections can extend beyond the vagina into the introitus and vulvar regions. Optionally, as shown in FIG. 3B, the device 110 may include an appendage 150, which may be permanently and/or integrally formed with the stiffening body 120 or membrane 130, or may be removably connected to the device 110, e.g., by a connector (not shown) on the body 120. The appendage 150 may include one or more leads 152 embedded within or otherwise carried by the appendage 150, which may be coupled to the light source(s) 140, e.g., to provide power to and/or otherwise operate the light source(s) 140.
For example, the appendage 150 may be connected or connectable to an external power supply or controller 160, which may selectively activate the light source(s) 140 during use. Alternatively, if the light sources 140 are optic fibers, the leads 152 may include optic fibers that may be optically coupled to the fibers within the device 110, and one or more LEDs or other light sources may be provided within the controller 160.
A connector (not shown) may be provided on one or both ends of the appendage 150, e.g., a first end that connects to the device 110 and a second end that connects to the power supply/controller 160. Alternatively, one or both ends may be permanently connected to the device 110 or the controller 160.
Optionally, the appendage 150 may include one or more additional LEDs or other light sources (not shown), e.g., along an inner curve, to radiate the introitus and vulvar regions of the patient. For example, the appendage 150 may be biased to a curved shape yet may be sufficiently flexible to facilitate introduction and/or removal of the device 110. In one embodiment, one end of the stiffening body may include an integral extension that provides the appendage 150. Alternatively, the appendage 150 may simply be a cable or other tether for connecting the device 110 to the power sour ce/contr oiler 160.
In a further alternative, the device 110 may include one or more of a controller, e.g., for operating the light source(s) 140 in a desired manner, a battery or other power source, and/or a wireless communications interface (not shown) carried on or in the device 110.
For example, such components may be embedded in the membrane 120, mounted on the stiffening body 130, and/or carried on an appendage 150 extending from the stiffening body 120
During use, the device 110 may be rolled, folded, or otherwise compressed into a contracted configuration, e.g., manually or using an insertion tool that constrains the device 110, a 90. Once positioned as desired, the device 110 may be released, whereupon the stiffening body 120 may resiliently deploy into an expanded configuration, which may position the membrane 130, and consequently, the light source(s) 140 adjacent desired tissue regions of the vagina 90 and/or vaginal canal. The light source(s) 140 may then be activated to treat an infection and then removed by the user, similar to other embodiments herein and in the applications incorporated by reference herein.
Optionally, the device 110 may have a length that is greater than its width, e.g., such that a first end of the device 110 may be positioned against or adjacent the cervix 92 while a second opposite end is positioned within the entrance to the vaginal cavity, e.g., such the appendage 150 extends from the vagina 90 (if provided). Optionally, the first end may have a curved and/or concave shape, e.g., to conform to the shape of the cervix 92, which may facilitate proper positioning of the device 110. If the device 110 does not include an appendage, the second end may include one or more features, e.g., tabs or holds, which may facilitate gripping the device 110 during introduction and/or removal after use.
In another alternative, a device for vaginal light therapy of a patient may be provided that includes a malleable body sized for introduction into a vaginal canal of the patient, and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light. In this alternative, the body may include an internal power source and/or controller, which may be used to selectively activate the light source(s). In a further alternative, an appendage may extend from one end of the body that includes one or more leads coupled to the one or more light sources for delivering power to the one or more light sources from an external power source and/or controller, similar to other embodiments herein. In this configuration, the malleable
material of the body may be manually manipulated to a desired shape, which may facilitate introduction and/or position of the device within the user’s vaginal canal for light therapy.
While the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents and alternatives falling within the scope of the appended claims.
Claims
1. A device for vaginal light therapy of a patient, comprising: an elongate member comprising a proximal portion, a distal portion sized for introduction into a vaginal canal, and one or more light sources on the distal portion; an expandable member carried on the distal portion and surrounding the one or more light sources, the expandable member configured to emit light outwardly from the one or more light sources at one or more wavelengths within a range of germicidal light; and an inflator for expanding the expandable member from a delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
2. The device of claim 1, wherein the inflator is connectable to the proximal portion of the elongate member and the elongate member includes an inflation lumen extending between the proximal and distal portions for delivering inflation media into an interior of the expandable member.
3. The device of claim 1, wherein the inflator is mounted on or in the elongate member and a valve is provided in the proximal portion for delivering inflation media via the inflator into an interior of the expandable member.
4. The device of claim 1, wherein the inflator comprises a manual or motorized pump.
5. The device of claim 1, wherein the inflator comprises a syringe filled with a predetermined volume of inflation media.
6. The device of claim 1, wherein the expandable member comprises a balloon formed from elastic material such that the balloon at least partially conforms to the subject’s anatomy when expanded.
7. The device of claim 1, wherein the expandable member comprises a balloon formed from elastic material configured to dilate the subject’s anatomy when expanded.
8. The device of claim 1, wherein the one or more light sources comprise a plurality of LEDs spaced apart from one another on the distal portion.
9. A device for vaginal light therapy of a patient, comprising: an elongate member comprising a proximal portion, and a distal portion sized for introduction into a vaginal canal; an expandable member carried on the distal portion carrying one or more light sources configured to emit light outwardly at one or more wavelengths within a range of germicidal light; and an inflator for expanding the expandable member from a delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
10. The device of claim 9, wherein the inflator is connectable to the proximal portion of the elongate member and the elongate member includes an inflation lumen extending between the proximal and distal portions for delivering inflation media into an interior of the expandable member.
11. The device of claim 9, wherein the inflator is mounted on or in the elongate member and a valve is provided in the proximal portion for delivering inflation media via the inflator into an interior of the expandable member.
12. The device of claim 9, wherein the inflator comprises a manual or motorized pump.
13. The device of claim 9, wherein the inflator comprises a syringe filled with a predetermined volume of inflation media.
14. The device of claim 9, wherein the expandable member comprises a balloon formed from elastic material such that the balloon at least partially conforms to the subject’s anatomy when expanded.
15. The device of claim 9, wherein the expandable member comprises a balloon formed from elastic material configured to dilate the subject’s anatomy when expanded.
16. The device of claim 1, wherein the one or more light sources comprise a plurality of LEDs spaced apart from one another on a wall of the expandable member.
17. The device of claim 1, wherein the one or more light sources comprises a plurality of optic fibers with ends spaced apart from one another and a light coupled to the optic fibers to deliver light through the fibers and out the ends outwardly from the expandable member.
18. The device of claim 17, wherein the light is provided in the inflator, and wherein the elongate member includes one or more source optic fibers communicating with the light and the optic fibers on the wall of the expandable member.
19. A device for vaginal light therapy of a patient, comprising: a stiffening body at least partially surrounding a central region; a flexible membrane carried by the stiffening body across the central region; and one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
20. The device of claim 19, wherein the stiffening body has an annular or “C” shape.
21. The device of claim 19, wherein the membrane is biased to a concave shape.
22. The device of claim 9, wherein the stiffening body is biased to an expanded configuration and is sufficiently flexible to be compressed to a contracted shape to facilitate in
23. The device of claim 19, wherein the one or more light sources comprise a plurality of LEDs spaced apart from one another on the diaphragm.
24. The device of claim 19 or 23, wherein the one or more light sources comprises a plurality of LEDs spaced apart from one another on the stiffening body.
25. A device for vaginal light therapy of a patient, comprising: a flexible membrane comprising a concave surface; a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient; and one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
26. The device of claim 25, wherein the membrane and stiffening body are biased to an expanded configuration and are sufficiently flexible to be compressed to a contracted shape to facilitate introduction of the device into a subject’s vagina.
27. The device of claim 26, wherein the stiffening body is biased to an annular shape in the expanded configuration and wherein opposite side regions of the stiffening body are compressible towards one another in the contracted shape.
28. The device of claim 26, wherein the stiffening body is biased to an annular shape in the expanded configuration and wherein the membrane and stiffening body are configured to be rolled into a tubular shape in the contracted shape.
29. The device of any one of claims 19-28, further comprising a power source carried by one of the membrane and the stiffening body, the power source coupled to the one or more light sources.
30. The device of claim 29, wherein the power source comprises a processor for selectively activating the one or more light sources.
31. The device of any one of claims 19-28, further comprising an appendage extending from one end of the stiffening body, the appendage comprising one or more leads
coupled to the one or more light sources for delivering power to the one or more light sources.
32. The device of claim 31, further comprising an external controller connected to the appendage for delivering power to the one or more light sources.
33. The device of claim 32, wherein the appendage comprises a first end connected to the stiffening body and a second end connected to the controller.
34. The device of claim 33, wherein the first end of the appendage is removable connected to the stiffening body.
35. The device of claim 33, wherein the second end of the appendage is removable connected to the controller.
36. The device of claim 31, wherein appendage comprises an elongate member ha stiffening member are introduced into the vaginal canal.
37. The device of claim 36, wherein the elongate member is flexible.
38. The device of claim 36, wherein the elongate member is malleable.
39. The device of claim 36, wherein the elongate member comprises a cable.
40. A device for vaginal light therapy of a patient, comprising: a malleable body sized for introduction into a vaginal canal of the patient; and one or more light sources carried by the body and configured to emit light outwardly at one or more wavelengths within a range of germicidal light.
41. The device of claim 40, further comprising an appendage extending from one end of the body, the appendage comprising one or more leads coupled to the one or more light sources for delivering power to the one or more light sources.
42. The device of claim 41, further comprising an external controller connected to the appendage for delivering power to the one or more light sources.
43. The device of claim 40, wherein the one or more light sources are carried within an interior of the body and wherein the body is substantially non-attenuating to the light transmitted by the one or more light sources.
44. A system for vaginal light therapy of a patient, comprising: a light treatment device comprising an elongate member including a proximal portion, a distal portion sized for introduction into a vaginal canal, one or more light sources, and an expandable member carried on the distal portion, the expandable member configured to emit light outwardly from the one or more light sources at one or more wavelengths within a range of germicidal light; and a controller comprising an inflator for expanding the expandable member from a delivery condition for introduction into a vaginal canal, and an expandable condition once inserted for delivering the light to treat one or more conditions.
45. The system of claim 44, wherein the one or more light sources comprises a plurality of optic fibers with ends spaced apart from one another on the expandable member and a light coupled to the optic fibers to deliver light through the fibers and out the ends outwardly from the expandable member.
46. The system of claim 44, wherein the one or more light sources comprises a plurality of optic fibers with ends spaced apart from one another on the expandable member, and wherein the device comprises an appendage extending from one end of the stiffening body and including a fiber optic cable coupled to the optic fibers to deliver light through the fibers and out the ends outwardly from the expandable member.
47. The system of claim 44, wherein the one or more light sources comprises a plurality of LEDs spaced apart from one another on the expandable member.
48. A system for vaginal light therapy of a patient, comprising:
a light treatment device comprising a flexible membrane, a stiffening body extending at least partially surrounding a perimeter of the membrane and sized for introduction into a vaginal canal of the patient, one or more light sources carried by one or both of the membrane or stiffening body configured to emit light outwardly at one or more wavelengths within a range of germicidal light; and a controller connectable to the device for activating the one or more light sources to deliver light therapy within the vaginal canal.
49. The system of claim 44, wherein the one or more light sources comprises a plurality of LEDs spaced apart from one another on the flexible membrane.
50. The system of claim 49, wherein the membrane is biased to a domed shape including a concave surface and a convex surface, and wherein the LEDs are mounted on one or both of the concave and convex surfaces.
51. The system of claim 44 or 48, wherein the controller comprises a power source connectable to the device for delivering power to the one or more light sources, and a processor for selectively controlling the power source to activate the one or more light sources to deliver light therapy within the vaginal canal.
52. The system of claim 44 or 48, wherein the one or more light sources comprise a plurality of optic fibers configured to emit light from one or both of the membrane and the stiffening body, and wherein the controller comprises an external light source and an optic fiber cable connectable to the device for delivering power to the plurality of optic fibers, and a processor for selectively controlling the activate light source to transmit light through the fiber optic cable and the plurality of optic fibers to deliver light therapy within the vaginal canal.
53. The system of claim 44 or 48, wherein the controller is configured to be programmed to activate the one or more light sources for a predetermined time during deliver of the light therapy.
54. A method for vaginal light therapy of a patient, comprising:
providing a treatment device comprising stiffening body and a diaphragm carried one or more light sources, the device in a contracted condition; inserting the device into a vagina in the contracted condition; releasing the device in the vagina such that the stiffening body opens to an expanded condition to deploy the diaphragm; activating the one or more light sources to emit light outwardly at one or more wavelengths within a range of germicidal light; and removing the device from the vagina after treatment.
55. The method of claim 54, wherein providing the treatment device comprises rolling, folding, or otherwise compressing the device from the expanded condition to the contracted condition before inserting the device.
56. The method of claim 54, wherein the stiffening body is biased to the expanded condition such that the device automatically expands towards the expanded condition when released in the vagina.
57. The method of claim 54, further comprising positioning the device in the vagina such that a concave surface of the diaphragm is positioned over the subject’s cervix.
58. The method of claim 54, further comprising coupling a controller to the device for delivering power to the one or more light sources.
59. A method for vaginal light therapy of a patient, comprising: providing a treatment device comprising an elongate member including a distal portion carrying an expandable member and one or more light sources; inserting the distal portion into a vaginal canal with the expandable member in a contracted condition; expanding the expandable member within the vaginal canal; activating the one or more light sources to emit light outwardly at one or more wavelengths within a range of germicidal light; and removing the device from the vaginal canal after treatment.
60. The method of claim 59, wherein expansion of the expandable member is monitored using external imaging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21793370.4A EP4138997A4 (en) | 2020-04-20 | 2021-04-20 | Vaginal light therapy devices and methods for using them |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063012700P | 2020-04-20 | 2020-04-20 | |
US202063012708P | 2020-04-20 | 2020-04-20 | |
US63/012,708 | 2020-04-20 | ||
US63/012,700 | 2020-04-20 | ||
US202017001609A | 2020-08-24 | 2020-08-24 | |
US17/001,609 | 2020-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021216605A1 true WO2021216605A1 (en) | 2021-10-28 |
Family
ID=78270004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/028235 WO2021216605A1 (en) | 2020-04-20 | 2021-04-20 | Vaginal light therapy devices and methods for using them |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4138997A4 (en) |
WO (1) | WO2021216605A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100298757A1 (en) * | 2009-05-19 | 2010-11-25 | Ams Research Corporation | Adjuvant enhanced ablation |
WO2014079972A1 (en) * | 2012-11-23 | 2014-05-30 | Photocure Asa | Device for photodynamic treatment |
US20160151639A1 (en) * | 2013-07-10 | 2016-06-02 | Oxys Ag | Devices and methods for delivery of therapeutic energy |
US20170072217A1 (en) * | 2009-01-12 | 2017-03-16 | Photocure Asa | Irradiation device |
US20180369603A1 (en) * | 2015-12-18 | 2018-12-27 | Photocure Asa | Device for photodynamic treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10004918B2 (en) * | 2014-07-03 | 2018-06-26 | Gregg Alan Klang | LED based vaginal light therapy device |
WO2017070155A1 (en) * | 2015-10-19 | 2017-04-27 | Christoph Scharf | Devices for delivery of repeatedly adjusted therapeutic light and devices for treatment of carbon monoxide poisoning |
JP2019517305A (en) * | 2016-05-31 | 2019-06-24 | シーダーズ−サイナイ メディカル センター | Internal UV treatment |
-
2021
- 2021-04-20 WO PCT/US2021/028235 patent/WO2021216605A1/en unknown
- 2021-04-20 EP EP21793370.4A patent/EP4138997A4/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170072217A1 (en) * | 2009-01-12 | 2017-03-16 | Photocure Asa | Irradiation device |
US20100298757A1 (en) * | 2009-05-19 | 2010-11-25 | Ams Research Corporation | Adjuvant enhanced ablation |
WO2014079972A1 (en) * | 2012-11-23 | 2014-05-30 | Photocure Asa | Device for photodynamic treatment |
US20160151639A1 (en) * | 2013-07-10 | 2016-06-02 | Oxys Ag | Devices and methods for delivery of therapeutic energy |
US20180369603A1 (en) * | 2015-12-18 | 2018-12-27 | Photocure Asa | Device for photodynamic treatment |
Non-Patent Citations (1)
Title |
---|
See also references of EP4138997A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP4138997A4 (en) | 2024-04-24 |
EP4138997A1 (en) | 2023-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11819245B2 (en) | Apparatus and methods for accessing and sealing bodily vessels and cavities | |
US10245074B2 (en) | Apparatus and methods for accessing and sealing bodily vessels and cavities | |
US10004918B2 (en) | LED based vaginal light therapy device | |
US10463530B2 (en) | Cervical stabilization device | |
JP2022550659A (en) | Abnormal uterine bleeding control system and method | |
JP2016536101A (en) | Cervical stabilization device | |
US11931595B2 (en) | Light-based vaginal therapy devices and methods for use | |
US20220331607A1 (en) | Light-based vaginal therapy devices and methods for use | |
CN111148543A (en) | Apparatus and method for eversion catheter with alignment and compliant pressurization | |
WO2021216605A1 (en) | Vaginal light therapy devices and methods for using them | |
WO2015070095A1 (en) | Apparatus and methods for accessing and sealing bodily vessels and cavities | |
CN217938294U (en) | Hemorrhoid compression hemostasis device providing observation visual field | |
EP3313513A1 (en) | Light-based vaginal light therapy device | |
WO2023041956A1 (en) | Endovaginal device for the correction of bladder and uterine prolapse incorporating a self-washing system with vaginal douches | |
CN113967309A (en) | Device for obstetrical and gynecological birth canal anti-inflammation medicine | |
WO2023212387A1 (en) | Light-based vaginal therapy devices and methods for use | |
MXPA99008930A (en) | Delivery preparation and facilitation device and preparatory gymnastics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21793370 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021793370 Country of ref document: EP Effective date: 20221121 |